Audit of 1 year survival for patients receiving chemotherapy for NSCLC - all comers

被引：0
|
作者：
Allison, J. L. E. [1 ]
Lord, H. [2 ]
机构：
[1] NHS Tayside, Med Oncol, Dundee, Scotland
[2] Univ Dundee, Ninewells Hosp & Med Sch, NHS Tayside, Oncol, Dundee DD1 9SY, Scotland
来源：
LUNG CANCER | 2016年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
81
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [31] 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%
    Gadgeel, S.
    Rodriguez-Abreu, D.
    Halmos, B.
    Garassino, M. C.
    Kurata, T.
    Cheng, Y.
    Jensen, E.
    Shamoun, M.
    Rajagopalan, K.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S77 - S78
  • [32] Audit of Patients Receiving Palliative Chemotherapy for Oesophagogastric Cancer at Velindre Cancer Centre in 2012
    Powell, C.
    Trickey, R.
    Morgan, C.
    CLINICAL ONCOLOGY, 2014, 26 : S1 - S1
  • [33] SURVIVAL OF PATIENTS WITH MALIGNANT-MELANOMA RECEIVING BCG WITH OR WITHOUT CHEMOTHERAPY
    GREEN, MD
    MACKAY, IR
    BUCKLEY, JC
    COATES, AS
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1979, 49 (03): : 335 - 339
  • [34] Long Term Survival Characteristics in SCLC Patients Receiving Atezolizumab and Chemotherapy
    Elegbede, A.
    Gibson, A.
    Pabani, A.
    Dean, M.
    Bebb, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1187 - S1188
  • [35] SURVIVAL AND PROGNOSIS IN PATIENTS WITH OSTEOGENIC-SARCOMA RECEIVING ADJUVANT CHEMOTHERAPY
    TRAPEZNIKOV, NN
    YEREMINA, LA
    KUTATELADZE, TO
    SINYUKOV, PA
    AMIRASLANOV, AT
    VOPROSY ONKOLOGII, 1984, 30 (07) : 33 - 40
  • [36] Survival of metastatic metaplastic breast cancer patients receiving chemotherapy.
    Kukunoor, Sparsha
    Lee, Anna
    Taiwo, Evelyn Oluwatoyin
    Schreiber, David
    Luhrs, Carol A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Does chemotherapy offer a survival benefit to NSCLC patients with a performance status of 2?
    Thompson, L.
    Lee, C.
    Burnett, A.
    LUNG CANCER, 2019, 127 : S48 - S49
  • [38] Induction chemotherapy in inoperable stage III α-β and IV NSCLC patients, evolution and survival
    Stathopoulos, GP
    Malamos, NA
    Papakostas, P
    Samelis, GF
    Rigatos, S
    Moschopoulos, N
    Papazachariou, A
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [39] Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
    Suresh, Karthik
    Psoter, Kevin J.
    Voong, Khinh Ranh
    Shankar, Bairavi
    Forde, Patrick M.
    Ettinger, David S.
    Marrone, Kristen A.
    Kelly, Ronan J.
    Hann, Christine L.
    Levy, Benjamin
    Feliciano, Josephine L.
    Brahmer, Julie R.
    Feller-Kopman, David
    Lerner, Andrew D.
    Lee, Hans
    Yarmus, Lonny
    Hales, Russell K.
    D'Alessio, Franco
    Danoff, Sonye K.
    Naidoo, Jarushka
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (03) : 494 - 502
  • [40] A clinical variable based nomogram could predict survival for NSCLC patients receiving atezolizumab
    Shang, X.
    Shi, J.
    Wang, X.
    Zhao, C.
    Yu, H.
    Wang, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1007 - S1007
12345